News

Thallion Pharmaceuticals, a biotechnology company developing pharmaceutical products in the areas of oncology and infectious disease, has reported a net loss of $3.24m or $0.10 per share in

ChemGenex Pharmaceuticals, an Australian biopharmaceutical development company, has completed a private placement to sophisticated and institutional investors in Australia and internationally to raise A$10m. ChemGenex placed 23.25 million

Celldex Therapeutics, a biopharmaceutical company, has expanded its precision targeted immunotherapy platform by acquiring exclusive rights to FMS-like tyrosine kinase 3 ligand and CD40 ligand, from Amgen. Specific

Array BioPharma, a biopharmaceutical company, has dosed its first type 2 diabetic patient in a Phase I clinical trial with its novel small molecule glucokinase activator, ARRY-403. In

“Mel has served as President and Chief Executive Officer of three healthcare companies, as well as having extensive management experience in operations, finance, sales and international market development

Tolera Therapeutics, a biotechnology company, has received orphan drug status from the FDA for its initial lead candidate, TOL101, for prophylaxis of acute rejection of solid organ transplantation.

Phadia, an in vitro allergy diagnostics company, has received the FDA clearance for its ImmunoCAP Rapid, the first point-of-care test to assist in the diagnosis of allergy in

Netherlands-based biopharmaceutical company Kiadis Pharma has reported promising preliminary clinical data on Atir showing its potential in mismatched bone marrow transplantations. The clinical results from 19 end stage

Alimera Sciences, a biopharmaceutical company engaged in the research, development and commercialization of prescription ophthalmic pharmaceuticals, has reported that an independent Data Safety Monitoring Board has recommended the